All AbMole products are for research use only, cannot be used for human consumption.

DIM-C-pPhOH (C-DIM8, CDIM8) is a nur77 (NR4A1) antagonist. Inhibits TGF-β induced cell migration of breast cancer cell lines. Promotes ROS/endoplasmic reticulum stress and proapoptotic pathways in pancreatic cancer cell lines. Mimics effects of Nur77 RNAi silencing. DIM-C-pPhOH decreases expression of β1-integrin protein and mRNA and β1-integrin-dependent responses in MCF7, MDA-MB-231, and SKBR3 cells and also inhibits migration of the latter two cell lines.
| Molecular Weight | 338.41 |
| Formula | C23H18N2O |
| CAS Number | 151358-47-3 |
| Form | Solid |
| Solubility (25°C) | DMSO ≥ 50 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Related Apoptosis Products |
|---|
| 23-Hydroxybetulinic acid
23-Hydroxybetulinic acid is a novel anticancer substance. |
| TH-302 (Evofosfamide)
TH-302 is a highly potent and selective hypoxia-activated procompound targeting hypoxic regions of solid tumors with IC50 of 19 nM. |
| Se-Methylselenocysteine
Se-methylselenocysteine, a precursor of methyl selenium, has strong cancer chemoprophylaxis and antioxidant activity. Se-Methylselenocysteine has oral biological activity, can induce apoptosis. |
| Aloperine
Aloperine is exhibits anti-inflammatory, antibacterial, antiviral, and anti-tumor properties. |
| Ezatiostat
Ezatiostat (TER199, TLK199) is a glutathione analog inhibitor of glutathione S-transferase (GST) P1-1. Ezatiostat leads to JNK activation by inhibiting GSTP1. Ezatiostat stimulates both lymphocyte production and bone marrow progenitor proliferation. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
